The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shan, D.
Right arrow Articles by Press, O. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shan, D.
Right arrow Articles by Press, O. W.

The Journal of Immunology, Vol 154, Issue 9 4466-4475, Copyright © 1995 by American Association of Immunologists

ARTICLES

Constitutive endocytosis and degradation of CD22 by human B cells

D Shan and OW Press
Department of Medicine, University of Washington, Seattle 98195, USA.

The CD22 B lymphocyte-surface Ag is an important component of the B cell-surface IgM (sIgM)/B cell receptor complex and has been shown to regulate B cell activation. In addition, this molecule has been shown to be an effective target for immunotherapy of B cell malignancies using immunotoxins and radioimmunoconjugates. In this report we describe the internalization and metabolic degradation of this molecule under constitutive conditions and after stimulation of B cells with phorbol dibutyrate or mAbs binding to sIgM, CD19, and CD22. Flow cytometry, "neuraminidase protection," and "neuraminidase shift" assays demonstrated that CD22 is internalized constitutively by unstimulated B cell lines and subsequently degraded in an acidic intracellular compartment (presumably lysosomes) without detectable recycling of the molecule back to the cell surface. Ligation of CD22 with anti-CD22 mAbs markedly increased CD22 internalization but did not affect the rate of intracellular degradation of CD22, suggesting that anti-CD22 mAbs perturb the intracellular trafficking of CD22. In contrast, CD22 internalization and degradation was unaffected by stimulation of B cell lines with phorbol dibutyrate or ligation of other components of the B cell receptor complex (e.g. CD19, sIgM) with mAbs. These patterns of internalization and degradation under constitutive and stimulated conditions contrast with those reported for other lymphoid differentiation Ags (e.g., the TCR, CD3, CD4, and the transferrin receptor), and may help explain the utility of this molecule as a target for immunoconjugate therapy.


This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
R. B. Walter, B. W. Raden, R. Zeng, P. Hausermann, I. D. Bernstein, and J. A. Cooper
ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2
J. Leukoc. Biol., January 1, 2008; 83(1): 200 - 211.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
H. Tateno, H. Li, M. J. Schur, N. Bovin, P. R. Crocker, W. W. Wakarchuk, and J. C. Paulson
Distinct Endocytic Mechanisms of CD22 (Siglec-2) and Siglec-F Reflect Roles in Cell Signaling and Innate Immunity
Mol. Cell. Biol., August 15, 2007; 27(16): 5699 - 5710.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. E. Collins, O. Blixt, S. Han, B. Duong, H. Li, J. K. Nathan, N. Bovin, and J. C. Paulson
High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells.
J. Immunol., September 1, 2006; 177(5): 2994 - 3003.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. M. Haas, S. Sen, I. G. Sanford, A. S. Miller, J. C. Poe, and T. F. Tedder
CD22 Ligand Binding Regulates Normal and Malignant B Lymphocyte Survival In Vivo.
J. Immunol., September 1, 2006; 177(5): 3063 - 3073.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Dunussi-Joannopoulos, G. E. Hancock, A. Kunz, M. Hegen, X. X. Zhou, B. J. Sheppard, J. Lamothe, E. Li, H.-L. Ma, P. R. Hamann, et al.
B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model
Blood, October 1, 2005; 106(7): 2235 - 2243.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
A. V. Rao, G. Akabani, and D. A. Rizzieri
Radioimmunotherapy for Non-Hodgkin's Lymphoma
Clin. Med. Res., August 1, 2005; 3(3): 157 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. F. DiJoseph, M. E. Goad, M. M. Dougher, E. R. Boghaert, A. Kunz, P. R. Hamann, and N. K. Damle
Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma
Clin. Cancer Res., December 15, 2004; 10(24): 8620 - 8629.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
M. Zhang and A. Varki
Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis
Glycobiology, November 1, 2004; 14(11): 939 - 949.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. F. DiJoseph, D. C. Armellino, E. R. Boghaert, K. Khandke, M. M. Dougher, L. Sridharan, A. Kunz, P. R. Hamann, B. Gorovits, C. Udata, et al.
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
Blood, March 1, 2004; 103(5): 1807 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Du, J. Honeychurch, M. S. Cragg, M. Bayne, M. J. Glennie, P. W. M. Johnson, and T. M. Illidge
Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy
Blood, February 15, 2004; 103(4): 1485 - 1494.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Carnahan, P. Wang, R. Kendall, C. Chen, S. Hu, T. Boone, T. Juan, J. Talvenheimo, S. Montestruque, J. Sun, et al.
Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22: Characterization of in Vitro Properties
Clin. Cancer Res., September 1, 2003; 9(10): 3982S - 3990.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Coleman, D. M. Goldenberg, A. B. Siegel, J. C. Ketas, M. Ashe, J. M. Fiore, and J. P. Leonard
Epratuzumab: Targeting B-Cell Malignancies through CD22
Clin. Cancer Res., September 1, 2003; 9(10): 3991S - 3994.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. John, B. R. Herrin, C. Raman, Y.-n. Wang, K. R. Bobbitt, B. A. Brody, and L. B. Justement
The B Cell Coreceptor CD22 Associates with AP50, a Clathrin-Coated Pit Adapter Protein, Via Tyrosine-Dependent Interaction
J. Immunol., April 1, 2003; 170(7): 3534 - 3543.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Lajaunias, L. Nitschke, T. Moll, E. Martinez-Soria, I. Semac, Y. Chicheportiche, R. M. E. Parkhouse, and S. Izui
Differentially Regulated Expression and Function of CD22 in Activated B-1 and B-2 Lymphocytes
J. Immunol., June 15, 2002; 168(12): 6078 - 6083.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman
Immunotherapy of Non-Hodgkin's Lymphomas
Hematology, January 1, 2001; 2001(1): 221 - 240.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. H. T. Chan, J. Wang, R. R. French, and M. J. Glennie
Internalization of the Lymphocytic Surface Protein CD22 Is Controlled by a Novel Membrane Proximal Cytoplasmic Motif
J. Biol. Chem., October 23, 1998; 273(43): 27809 - 27815.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Razi and A. Varki
Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes
PNAS, June 23, 1998; 95(13): 7469 - 7474.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Funaro, M. Reinis, O. Trubiani, S. Santi, R. Di Primio, and F. Malavasi
CD38 Functions Are Regulated Through an Internalization Step
J. Immunol., March 1, 1998; 160(5): 2238 - 2247.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.